“The commercial availability of HTPs in Japan is associated with a significant drop in conventional cigarette sales, well ahead of the previous rate of decline. Moreover, even after HTPs became available, sales of all tobacco products (HTPs and conventional cigarettes) continued to fall. Although there is mixed evidence, data from the 2019 National Health Survey indicates that 76% of consumers who use HTPs do so exclusively. Only 24% of HTP users maintain dual-use,” explained Mark Dougan, Consulting Director, Healthcare, Frost & Sullivan.
Dougan added, “The Japanese government is differentiating HTPs from conventional cigarettes in regulations such as taxation, health warnings and indoor use restrictions, with HTPs generally receiving less-stringent regulatory settings than conventional cigarettes.”
Globally, smoking is the leading preventable cause of premature mortality and morbidity, with over 7 million mortalities from smoking-related diseases and a further 1.2 million from exposure to tobacco smoke. Overall, based on the data from Japan, the following trends have been identified:
- Between 2015 and 2019, the total cigarette sales in Japan dropped by 34%, which can be associated with the commercial launch of HTPs.
- The regulatory framework for HTPs is increasingly diverging from the framework governing conventional cigarettes in terms of taxation, health warnings, and restrictions on use.
- The availability of HTPs has had a low impact on the initiation of tobacco use by never-smokers and re-initiation by former smokers.
- HTPs are also less likely to cause household fires than conventional cigarettes, which are the leading cause of household fires in Japan.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.